In rats, chronic treatment with lithium elicits a dose-dependent increase in the [Met5] Lithium administration relieves mania and some depressions and prevents the recurrence of manic depressive illness by unknown mechanisms (1-3). A better understanding of the molecular mechanism involved in this therapeutic action would increase our present knowledge of the pathophysiology of manic depressive illness and would help to develop better therapeutic agents. Like sodium, lithium influences the high-affinity binding of agonists and antagonists to opiate receptors (4). Therefore, lithium could modify opiate receptor affinity by changing receptor conformation, thereby reducing or increasing the activity of endogenous enkephalinergic neuronal systems. Consistent with this prediction, lithium administration has been reported to antagonize codeine analgesia (5). Other reports have shown that lithium increases morphine analgesia but fails to change development of tolerance to the opioid (6).
[Leu5]enkephalin content by an extent equal to the increase of [Met jenkephalin. Based on the characteristics of the lithiuminduced increase in [Met5Jenkephalin content, it is pro'osed that lithium may reduce the rate of release of [Met5Jenkephalin from the small enkephalinergic neurons that are intrinsic to the striatum; this action may be related to a change in the regulation of striatal neurons.
Lithium administration relieves mania and some depressions and prevents the recurrence of manic depressive illness by unknown mechanisms (1) (2) (3) . A better understanding of the molecular mechanism involved in this therapeutic action would increase our present knowledge of the pathophysiology of manic depressive illness and would help to develop better therapeutic agents.
Like sodium, lithium influences the high-affinity binding of agonists and antagonists to opiate receptors (4) . Therefore, lithium could modify opiate receptor affinity by changing receptor conformation, thereby reducing or increasing the activity of endogenous enkephalinergic neuronal systems. Consistent with this prediction, lithium administration has been reported to antagonize codeine analgesia (5) . Other reports have shown that lithium increases morphine analgesia but fails to change development of tolerance to the opioid (6) .
Modifications of the sensitivity of the brain receptor for catecholamines have been proposed to underlie a number of psychopathologies, including depressive disorders (7) . That lithium may affect catecholamine receptors was suggested by reports that it antagonizes the norepinephrine-induced inhibition of the stimulation of platelet adenylate cyclase and cyclic AMP production by prostaglandin E1 (8) . In addition, chronic administration of lithium (9), but not short-term administration (10) , has been reported to decrease dopamine synthesis from [3H]tyrosine in rats. Perhaps the action of lithium on catecholamine metabolism reflects a modification in the responsiveness of regulatory presynaptic receptors to endogenous ligands such as enkephalins or endorphins. Recent evidence has indicated that small enkephalinergic neurons intrinsic to the striatum (11) form axo-axonic synapses with striatal dopami- (13) . The brain was sliced into 400 Asm sections in a cryostat at -10°. Brain nuclei were punched from the frozen sections with various sizes of stainless steel needles, by the method of Palkovitz (14) , as described by Koslow et al. (15) . Tissue was homogenized with 0.1 M acetic acid and centrifuged at 25,000 X g for 20 min. The supernatant fluid neutrialized with 1 M NaOH was then radioimmunoassayed for [Met5*enkaphalin. For the production of serum directed toward [Met5]enkaphalin, succinyl-[Met5]enkaphalin and succinylhemocyanin were coupled to polylysine with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The conjugate, emulsified in complete Freund's adjuvant,-was injected intradermally into four sites of the rabbit's back. The injections were repeated at 2-week intervals and the animals were bled after the sixth injection. The assay was carried out in polypropylene tubes. Labeled peptide or brain extract was incubated with antiserum diluted 2000-fold and tritiated [Met5]enkephalin in 0.5 ml of 0.2 M Tris buffer (pH 7.4) containing 0.1% albumin and 0.06% dextran (wt/vol). The incubation was carried out at 40 for about 24 hr. The tritiated [Met5]enkephalin.bound to the antibody was separated from the free tritiated [Met5]enkephalin by adding 0.2 ml of 1.5% charcoal slurrey containing 0.15% dextran and 0.9% NaCl (wt/vol), and the radioactivity of an aliquot of the supernatant fluid was measured in a Beckman LS 250 liquid scintillation spectrometer.
Under our conditions, the minimum detection limit was 50 fmol of [Met5]enkephalin. In the brain, the decline of the im- (Fig. 1) . The extent of the increase was proportional to the duration of the treatment up to 5 days; thereafter, it reached a plateau which was maintained up to 7 days of treatment at a concentration 2.5 times that of normal rats (Fig. 1) 
